CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- FinancialsAltman Z-Score 4.06: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.49BCNY666.58M · vs all stocks (USD)
Revenue (TTM)
456.44MCNY67.79M · vs all stocks (USD)
Profit Margin
-10.76%vs Medical Devices peers
Beta
0.1190xvs all stocks
52-Week Change
-34.39%vs all stocks
Market Capitalization
4.49BCNY666.58M · vs all stocks (USD)
Enterprise Value
3.60BCNY535.38M · vs all stocks (USD)
Price to Sales (TTM)
10.24xvs Medical Devices peers
Price to Book (MRQ)
2.71xvs Medical Devices peers
Enterprise to Revenue
7.90xvs Medical Devices peers
Enterprise to EBITDA
-89.32xvs Medical Devices peers
Gross Margin
51.79%vs Medical Devices peers
Profit Margin
-10.76%vs Medical Devices peers
Operating Margin
-1.86%vs Medical Devices peers
Return on Assets (TTM)
-1.47%vs Medical Devices peers
Return on Equity (TTM)
-2.73%vs Medical Devices peers
Revenue (TTM)
456.44MCNY67.79M · vs all stocks (USD)
Revenue per Share (TTM)
1.12CNYUpdated Aug 20, 2026Quarterly Revenue Growth
-10.30%vs Medical Devices peers
Gross Profit (TTM)
182.57MCNY27.12M · vs all stocks (USD)
EBITDA (TTM)
63.09MCNY9.37M · vs all stocks (USD)
Net Income (TTM)
-49.10MCNY-7.29M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-31.28%vs Medical Devices peers
Operating Cash Flow (TTM)
18.97MCNY2.82M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-44.04MCNY-6.54M · vs all stocks (USD)
5-Year Average Dividend Yield
1.31%vs all stocks
Payout Ratio
23.40%vs Medical Devices peers
Revenue
468.00MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
243.14MCNYFY2025 · Dec 31, 2025Gross Profit
224.86MCNYFY2025 · Dec 31, 2025Operating Income
-13.98MCNY-2.08M · vs all stocks (USD)
Pre-tax Income
-26.89MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.46MCNYFY2025 · Dec 31, 2025Net Income
-24.42MCNYFY2025 · Dec 31, 2025EBIT
10.54MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
63.09MCNYFY2025 · Dec 31, 2025Research & Development
91.66MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
101.13MCNYFY2025 · Dec 31, 2025Other Operating Expenses
8.75MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
49.80MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
37.43MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
407.06MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
407.06MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-24.42MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-4.21MCNYFY2025 · Dec 31, 2025Free Cash Flow
-53.54MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
982.72MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-24.42MCNYFY2025 · Dec 31, 2025Other Non-cash Items
19.53MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-10.46MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
11.14MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.33MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.80BCNYFY2025 · Dec 31, 2025Sale of Investments
4.08BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
227.79MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
275.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-120.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-112.11MCNYFY2025 · Dec 31, 2025Other Financing Charges
20.63MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
63.52MCNYFY2025 · Dec 31, 2025Shares Outstanding
401.80MSharesUpdated Aug 20, 2026Float Shares
198.16MSharesUpdated Aug 20, 2026% Held by Insiders
52.15%vs all stocks
% Held by Institutions
1.54%vs all stocks
Total Cash (MRQ)
2.05BCNY304.98M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.11CNYUpdated Aug 20, 2026Total Debt (MRQ)
985.26MCNY146.33M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5715xvs Medical Devices peers
Current Ratio (MRQ)
7.80xvs Medical Devices peers
Book Value per Share (MRQ)
4.29CNYUpdated Aug 20, 2026Total Assets
2.77BCNY411.58M · vs all stocks (USD)
Total Current Assets
2.34BCNYFY2025 · Dec 31, 2025Total Liabilities
1.04BCNYFY2025 · Dec 31, 2025Total Non-current Assets
427.44MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
758.55MCNYFY2025 · Dec 31, 2025Total Current Liabilities
279.50MCNYFY2025 · Dec 31, 2025Cash
982.62MCNYFY2025 · Dec 31, 2025Cash Equivalents
104.87KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
982.72MCNYFY2025 · Dec 31, 2025Other Short-term Investments
631.77MCNYFY2025 · Dec 31, 2025Accounts Receivable
50.05MCNYFY2025 · Dec 31, 2025Inventory
229.58MCNYFY2025 · Dec 31, 2025Accounts Payable
11.47MCNYFY2025 · Dec 31, 2025Short-term Debt
216.08MCNYFY2025 · Dec 31, 2025Long-term Debt
751.40MCNYFY2025 · Dec 31, 2025Common Stock (Book)
401.80MCNYFY2025 · Dec 31, 2025Retained Earnings
767.53MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.73BCNY257.41M · vs all stocks (USD)
52-Week Low
9.98CNYUpdated Aug 20, 202652-Week High
18.75CNYUpdated Aug 20, 202652-Week Change
-34.39%vs all stocks
Beta
0.1190xvs all stocks
50-Day MA
10.92CNYUpdated Aug 20, 2026200-Day MA
13.69CNYUpdated Aug 20, 2026Avg 10-Day Volume
3.95MSharesUpdated Aug 20, 2026Avg 30-Day Volume
4.23MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.1200CNYUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Long-Term Debt A High Share Of Total Liabilities, Short-Term Debt A High Share Of Current Liabilities
Borrowing makes up most of what it owes, both the long-dated part and the part due soon.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.52Profit Margin: -0.11
Financial Health
Altman Z-Score 4.06: safe zoneNotable
Altman Z-Score: 4.06
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Yatai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tibet Duorui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Lisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CorMedix Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
LivsMed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sinotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Opendoor Technologies Inc.
2 interpretationsLong-Term Debt A High Share Of Total Liabilities, Short-Term Debt A High Share Of Current LiabilitiesCash Elevated Relative to Current Liabilities and Total Assets
Bitfarms Ltd.
2 interpretationsLong-Term Debt A High Share Of Total Liabilities, Short-Term Debt A High Share Of Current LiabilitiesCash Elevated Relative to Current Liabilities and Total Assets
Anbio Biotechnology Limited
1 interpretationCash Elevated Relative to Current Liabilities and Total Assets